Conclusions
In low-risk surgical patients with AS, the clinical efficacy of TAVI was superior to that of SAVR at the 30-day and 1-year follow-up. At the 2-year follow-up, with the exception of the decreased NAF risk, there was no significant difference in all-cause mortality, cardiovascular mortality, and life-threatening or significant bleeding. However, potential late TAVI-associated complications, such as valvular degeneration and PPI are important clinical concerns that must be considered when weighing treatment options for AS.